This year, at the International Workshop on HIV Pediatrics and IAS our ODYSSEY and SMILE studies and EPIICAL will be presenting abstracts in various sessions.
The International Workshop on HIV Pediatrics 2021 will be taking place from the 16th to the 17th of July 2021. It is considered to be the only meeting entirely devoted to research in the prevention and treatment of HIV infections in infants, children, and adolescents, making it the premier forum for the world’s leading researchers. Find out more about the workshop here.
Penta presentations: HIV Pediatics Workshop Pediatric treatment Session | |
ODYSSEY | Dolutegravir-Based ART is superior to Standard of Care in young children living with HIV. Pauline Amuge |
SMILE | Once-Daily Integrase Inhibitor (Insti) With Boosted Darunavir is Non- Inferior to Standard of Care in Virogically Suppressed Children, Week 48 Results of the SMILE PENTA-17 Trial. Alexandra Compagnucci |
Complications of Pediatric or Maternal ART – Abstract session 2 | |
ODYSSEY | Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial. Ciccy Kityo |
ODYSSEY | Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial. Hilda Angela Mujuru |
Poster Presentations | |
EPIICAL | Early-Treated Infants living with HIV typically recover their Cd4+ T-Cell counts but not their Cd4+ T-cell percentages. Juliane Schröter, Anet J.N. Anelone & Rob J. de Boer (on behalf of the EPIICAL consortium) |
ODYSSEY | Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial. |
ODYSSEY | No age-related difference in dolutegravir metabolic glucuronidation ratio in children between 3 months and 18 years old in the ODYSSEY trial |
ODYSSEY | Effect of dolutegravir on folate and vitamin B12 status among HIV-infected children and adolescents in the ODYSSEY trial |
ODYSSEY | Exposure to two dolutegravir formulations in children in the ODYSSEY trial |
IAS will be held from the 18th till the 21st of July 2021 as a hybrid congress, making it accessible to more researchers across the globe. IAS is considered the world’s most influential conference on HIV Science. Find out more about IAS here
Penta presentations: IAS On demand oral abstract session | |
ODYSSEY | Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial. Anna Turkova |
Pharmacokinetics, pharmacodynamics, pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations | |
ODYSSEY | On demand e poster: No age-related difference in dolutegravir metabolic glucuronidation ratio in children between 3 months and 18 years old in the ODYSSEY trial. Tom Jacobs |
Clinical trials in paediatric and adolescent populations | |
ODYSSEY | Effect of dolutegravir on folate and vitamin B12 status among HIV-infected children and adolescents in the ODYSSEY trial. Linda Barlow-Mosha |
ODYSSEY | Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial. Anna Turkova |
SMILE | Once-Daily Integrase Inhibitor (Insti) With Boosted Darunavir is Non- Inferior to Standard of Care in Virogically Suppressed Children, Week 48 Results of the SMILE PENTA-17 Trial. Alexandra Compagnucci |
ODYSSEY | A randomised comparison of DTG-based ART vs Standard of Care in infants and young children living with HIV weighing 3 to 14kg: results from the ODYSSEY trial. Abbas Lugemwa |
ODYSSEY | Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial. Cissy Kityo |